Asep Medical Holdings Inc. is Granted Patent Approval for its AI-based Sepsis Diagnostic Technology in the US

Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that the Company’s AI-based sepsis diagnostic technology, called SepsetER TM, has received successful patent approval in the United States. The Company received confirmation from its attorneys of its US Patent Application No. 16/279788, which has been subsequently validated in the US, representing 332 million people. This patent is in addition to the successful European and Australian patents awarded to the Company in November of 2022, which represent approximately 400 million people.

The US patent, granted on August 18, 2023, is exclusively licensed to Asep Inc.’s subsidiary Sepset Biosciences Inc. and validates the Company’s unique AI-based approach to sepsis diagnosis, a disease that globally causes more than 11 million deaths annually. SepsetER TM is a blood-based gene expression assay developed under the direction of leading UBC microbiologist and Asep Inc.’s Founder, Chair & CEO, Dr. Robert E. W. Hancock. The test enables earlier and faster risk assessment of sepsis and enables targeted treatment. Sepsis is also the cause of death in most patients with severe COVID-19.

The patents also provide a solid foundation for the Company’s business since the test is in advanced development and in preparation for formal clinical 510(k) studies in the United States. Since the SepsetER signature has already been validated and refined in more than 700 sepsis and severe COVID-19 patients to date, the Company is looking to duplicate this in a formal trial. In the diagnostics area, the 510(k) route involves a single clinical study that, if successful, will lead to approval by the US Food & Drug Administration (FDA). Once approved, the test will be marketed for use in emergency rooms and intensive care units worldwide, enabling physicians to make early informed decisions about patient care that will improve prognosis and survival.

The SepsetER TM test senses the dysfunctional immune response underlying sepsis when patients first enter the emergency room. The test is a blood-based gene expression assay that is straightforward to implement using equipment available in most hospital labs, and results are obtained in about 60-90 minutes. Current diagnostic tools deliver results after approximately 8-36 hours, often delaying the initiation of treatment. SepsetER TM is designed to enable physicians to quickly predict how severe the disease will become and thus trigger urgent patient treatment.

CEO Dr. Robert E. W. Hancock stated, “Patents are the lifeblood of biotechnology companies like ours. This new patent in the US once again validates the novelty of our technology in major markets, which now represents over 700 million people.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Michael Dabrowski, CEO of Pelago Bioscience "We are grateful to the University of Edinburgh in their acknowledgement of our Patent. I encourage the drug discovery community to engage with Pelago Bioscience to explore the value that our patented CETSA technology and services can bring to enhance their drug discovery efforts.
The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.

By using this website you agree to accept Medical Device News Magazine Privacy Policy